Shuchismita Dutta

Nipah #virus is bat-borne & highly pathogenic in humans. Structures of the viral polymerase complex (polymerase, L & phosphoprotein, P), provide insights for rational design of antiviral drugs. doi.org/10.1016/j.cell…; doi.org/10.1038/s44318…

O-GlcNAcylation, a post-translational modification of tau & other proteins, is decreased in #Alzheimers disease. Ceperognastat, inhibits O-GlcNAcase, and enzyme that catalyzes the removal of O-GlcNAc from tau, so it can slow progression of the disease!

Gabapentin (magenta) was approved by @US_FDA as an anti-epileptic & for treating seizures. It inhibits voltage-gated calcium channels & is also widely used to treat neuropathic pain. (calcium shown as red sphere) doi.org/10.1038/s41594…

Many gastrointestinal #Cancer are driven mutant KIT tyrosine kinase. Commonly treated with type II KIT inhibitors (eg, imatinib and sunitinib), adding type I or active-state KIT inhibitor (eg, pexidartinib) can broad mutation coverage. @US_FDA #Storytelling

With gratitude for what I have learned in the past years I welcome a new chapter in 2025. #MolecularStorytelling #scicomm #MolecularVisualization

Tovorafenib, a type II RAF kinase inhibitor was approved by @US_FDA to treat a type of brain tumour in children - e.g., relapsed or refractory pediatric low-grade glioma esp. with BRAF gene mutations (e.g., V600E). #Cancer #BRAIN

Lazertinib a tyrosine kinase inhibitor (TKI) was approved by @US_FDA in Aug 2024 for EGFR mutant (e.g., L858R/T790M) non-small cell lung #cancer. It is is used alone or in combination with other #chemotherapeutic agents.

Human TCR and HLA-A1 major histocompatibility complex (MHC) can recognize NRAS neoantigens peptides with Q61K and Q61R mutations versus wild-type NRAS peptide. #cancer #AlphaFold

In October @US_FDA approved inavolisib, a PI3Kα Inhibitor to treat locally advanced or metastatic breast #Cancer. It was approved for use with with palbociclib and fulvestrant.

Acute leukaemias require chromatin adapter protein menin (MEN1 gene product) function. Last month, menin inhibitor revumenib was approved by @US_FDA for treating refractory acute leukemia.

Thank you @TracieAddy for organizing the community reading on Enhancing #inclusive Instruction this semester. I am inspired to learn more and apply this learning.

Last month @US_FDA approved the 1st biparatopic antibody therapy (Zanidatamab) for metastatic HER2+ billiary tranct #Cancer. The bispecific antibodies simultaneously targets 2 regions of HER2 - dimerization & extracellular juxtamembrane domains, nature.com/articles/d4157…

Congratulations @calebtru on the publication of this blog about #MolCaseNet. uwb.edu/news/2024/11/2… #storytelling

Metformin bound to SLC22A1, a transporter involved in uptake of the #diabetes treatment medicine metformin. see PDB ID 8jtt (rcsb.org/structure/8JTT). #WorldDiabetesDay2024

It is free to attend but you have to register forms.gle/qBJeoVf8cxJTuE…. Hope you can join us on Nov 4, 2024 at 1p ET to visualize and #explore #Plant #protein

Join us on Nov 4, 2024 @ 1p ET for this year's last Mol* Office Hour to explore #Plant (e.g., rice, lupine, peanuts, and more) proteins. Register (forms.gle/qBJeoVf8cxJTuE…). Learn more at rcsb.org/news/feature/6… @Omeiza_PlantDoc @dennisgameplay @rajarshi_sanyal @plantae_org

Have questions about biomolecular visualization using RCSB.org Mol*? Share your #questions and register here (forms.gle/qBJeoVf8cxJTuE…) to join us in the next Office Hour on Sep 9, 2024 at 1p ET. Learn more at rcsb.org/news/feature/6…

Join in this webinar to bring RCSB.org and related rata, tools, and resources into your classroom. Register for free today rcsb.org/news/feature/6… #enzymes #molecularmedicine

Excited about the positive energy on the last day of the #BIOME2024. Looking forward to the #workinggroup and #FMN s this fall.

Thank you Pat Marsteller for an inspiring discussion about wicked problems in #STEMeducation. #Biome2024